Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.41 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.41 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 7/20 | 0.37 |
| ▸ | PIM1 | P11309 | 5/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956106 | 1.00 | CYP2A6 (0.41) | CYP2A6TRIM24TRIM33IMPDH2PIM3 | |
| SCHEMBL29953700 | 0.85 | CYP2A6 (0.37) | CYP2A6TRIM24TRIM33IMPDH2PIM3 | |
| SCHEMBL29957429 | 0.85 | CYP2A6 (0.37) | CYP2A6TRIM24TRIM33IMPDH2PIM3 | |
| SCHEMBL671969 | 0.85 | TRIM24 (0.47) | CYP2A6TRIM24TRIM33IMPDH2PIM3 | |
| SCHEMBL29954403 | 0.85 | ERN1 (0.42) | CYP2A6TRIM24TRIM33IMPDH2PIM3 | |
| SCHEMBL3034999 | 0.85 | CYP2A6 (0.37) | CYP2A6TRIM24TRIM33IMPDH2PIM3 | |
| SCHEMBL29952089 | 0.85 | ERN1 (0.42) | CYP2A6TRIM24TRIM33IMPDH2PIM3 | |
| SCHEMBL29951137 | 0.81 | KMT2A (0.42) | TRIM24TRIM33PIM3PIM1TDP1 | |
| SCHEMBL29958363 | 0.81 | KMT2A (0.45) | TRIM24TRIM33TDP1ALDH1A1KMT2A | |
| SCHEMBL22126572 | 0.73 | CYP2A6 (0.50) | CYP2A6IMPDH2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2605658-B1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME (US) | 2016-03-23 | — | — | EP | disclosed |
| US-8742110-B2 | Spiroxazolidinone compounds | MERCK SHARP & DOHME CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2605658-A1 | SPIROXAZOLIDINONE COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2013-06-26 | — | — | EP | disclosed |
| US-20130131042-A1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2571356-A1 | SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2013-03-27 | — | — | EP | disclosed |
| US-20130040978-A1 | SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS | MERCK SHARP & DOHME CORP | 2013-02-14 | — | — | US | disclosed |
| US-20130040978-A1 | SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS | MERCK SHARP & DOHME CORP | 2013-02-14 | — | — | US | disclosed |
| US-20130040978-A1 | SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS | MERCK SHARP & DOHME CORP | 2013-02-14 | — | — | US | disclosed |
| WO-2012024183-A1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2012-02-23 | — | — | WO | disclosed |
| WO-2011146324-A1 | SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011146324-A1 | SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131042-A1 | SPIROXAZOLIDINONE COMPOUNDS | SSTR5, SSTR2, SSTR4 | CYP2A6 1930/4885TRIM24 4041/4885TRIM33 4655/4885 |
| US-20130040978-A1 | SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS | SSTR5, SSTR2, SSTR1 | CYP2A6 2727/4885TRIM24 4468/4885TRIM33 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.